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A critical component of an effective HIV vaccine will be the induction of broadly neutralizing antibodies. Comprising the HIV spike, the
exterior envelope glycoprotein gp120 and the transmembrane glycoprotein gp41 mediate receptor binding, viral entry, and are the targets for
neutralizing antibodies. The gp120 and gp41 glycoproteins are derived from the gp160 precursor glycoprotein and following gp160
glycosylation, oligomerization and cleavage in the endoplasmic reticulum and Golgi, remain as non-covalently associated trimers of
heterodimers. Previously, using cell-surface envelope glycoproteins derived from infection of a laboratory-adapted HIV-1 strain, a correlation
had been established between the binding of gp120-directed antibodies to the viral glycoprotein and the ability of the antibodies to neutralize
laboratory-adapted isolates. However, this has been more difficult to demonstrate for glycoproteins derived from primary patient isolates.
Here, using a FACS-based method, we report that only gp120-directed neutralizing antibodies and the neutralizing ligand soluble CD4
efficiently bind to glycoproteins derived from the JR-FL primary isolate provided that the gp160 precursor protein is efficiently cleaved.
Precursor cleavage was demonstrated by cell-surface biotinylation and Western blotting. In stark contrast, both non-neutralizing and
neutralizing antibodies bind non-cleaved envelope glycoproteins from JR-FL and YU2 isolates. These data imply that significant changes in
Env spike structure are dependent upon precursor gp160 cleavage and are consistent with a restricted-binding-to-Env model of neutralization.
The data also have implications in regards to the use and design of non-cleaved envelope glycoprotein trimeric immunogens as a means to
selectively and preferentially present neutralizing epitopes to the host immune system.
Published by Elsevier Inc.
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The HIV-1 envelope glycoproteins are located on the
surface of the virus and as such are the sole targets for
neutralizing antibodies. The concerted and complex inter-
actions with the viral receptors CD4 and CCR5/CXCR4
mediate viral binding, fusion, and entry (Choe et al., 1996;
Dalgleish et al., 1984; Deng et al., 1996; Wu et al., 1996).
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E-mail address: richardwyatt@nih.gov (R. Wyatt).gp41 are derived from a gp160 precursor glycoprotein
following cleavage to form a trimer of noncovalently
associated heterodimers (Center et al., 2002; Hallenberger
et al., 1992; Weissenhorn et al., 1997; Willey et al., 1988).
The gp120–gp41 interaction is potentially unstable,
although recent data suggest that for many viral strains,
once the mature Env spike glycoproteins are incorporated
into the lipid bilayer of the virus, the association is
relatively stable and that the incorporated envelope glyco-
proteins are fully cleaved (Chertova et al., 2002; Zhu et al.,
2003).
However, controversy yet exists regarding the potential
for incorporation of uncleaved gp160 into virions (Chertova05) 145–156
Fig. 1. Neutralization curves of wild-type JR-FL-GFP viruses with 2G12,
the CD4BS antibodies IgGb12, F105 and IgGb6, sCD4 and the V3 loop
monoclonal antibody, 39F. The values are presented as percent residual
entry and are normalized to 100% virus entry into PBMC target cells in
absence of ligands (see Materials and methods).
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Controversy also exists regarding the impact of the cleavage
event on overall Env spike architecture, which, in the
absence of an atomic level structure, can currently only be
assessed by indirect means (Binley et al., 2000, 2002; Si et
al., 2003; Stamatatos et al., 2000). Lacking direct structural
information, it is not certain if the gp160 precursor cleavage
event only subtly alters the trimeric spike architecture as is
the case for the structurally defined cleavage of influenza
HA0 to HA1/2, or if cleavage causes more significant
rearrangements as has been implicated for other viral
envelope glycoproteins (Binley et al., 2002; Chen et al.,
1998, 2001; Gibbons et al., 2004; Kenney et al., 1994;
Morrison, 2003; Skehel and Wiley, 2000).
HIV-1 is relatively resistant to antibody-mediated
neutralization with only a handful of human monoclonal
antibodies isolated from HIV-infected individuals being
capable of neutralizing a broad array of primary isolates.
One model of neutralization suggests that if an antibody
binds to the HIV functional spike with sufficient affinity
and occupancy, the ligand will neutralize the virus
regardless where it actually binds on the spike (Parren
et al., 1998). This model is referred to here as the
restricted-binding-to-Env model. The mechanism of the
neutralization may simply be that one antibody binds per
functional trimer and thereby sterically interferes with the
coupled processes of receptor–coreceptor engagement,
envelope glycoprotein conformational changes, membrane
fusion, and viral entry.
In this model, binding to the functional spike would
correlate with the capacity to neutralize the virus. Such a
correlation was shown nearly a decade ago for cells
infected with a laboratory-adapted HIV-1 isolate and
analyzed with a set of anti-gp120 antibodies that could or
could not neutralize the virus (Sattentau and Moore,
1995). However, the application of this system and the
extension of these results have been difficult to reproduce
for primary isolates due to low Env expression, incom-
plete precursor cleavage, oligomeric Env heterogeneity, or
relatively poor incorporation of functional Env into
virions. In studies that examined primary isolate virions
or env-transfected cells, no consistent correlation between
antibody binding to Env and neutralization capacity could
be observed (Grundner et al., 2002; Herrera et al., 2003;
Poignard et al., 2003; York et al., 2001). Previously,
using cell-surface ELISA, an association between neu-
tralization and binding to oligomeric envelope glycopro-
teins from a primary isolate has been demonstrated (Fouts
et al., 1997). More recently, using FACS (fluorescence
activated cell sorting)-based cell-surface staining, we
could observe a correlation between increased binding
to a glycosylation-modified primary isolate Env by a set
of antibodies and the relative increased neutralization
sensitivity of the corresponding glycosylation-modified
virus by these same antibodies (Koch et al., 2003). In a
previous study, we have shown that primary isolate Envglycoproteins expressed on cell surfaces following tran-
sient transfection are oligomeric and are predominantly
trimers (Grundner et al., 2002).
Here, we demonstrate a correlation between the
capacity of antibody and ligand to neutralize a primary
isolate and binding to the functional, cleaved envelope
glycoproteins derived from the same virus. We can
observe this correlation for one strain of cleavage-
competent primary isolate Env (JR-FL), but the correla-
tion is lost if the efficiently cleaved Env is rendered
cleavage-defective by design. These results imply that
efficient HIV-1 envelope glycoprotein precursor cleavage
is required for selective recognition by neutralizing
ligands. Furthermore, correlations between binding and
neutralization are not observable for primary envelope
glycoproteins that exhibit markedly less efficient gp160
precursor cleavage (YU2). Together, these data imply that
precursor cleavage has a significant impact on gp120
envelope glycoprotein antigenic structure. Such an inter-
pretation agrees with a previous study that demonstrated
preferential recognition of cleaved Env by the neutraliz-
ing antibody IgGb12 (Roben et al., 1994), but contrasts
with the study by Si et al. (2003), which concluded that
Env topology was not significantly affected by proteolytic
precursor cleavage. These observations may impact HIV
subunit vaccine design since most soluble gp140 glyco-
proteins that attempt to mimic the functional viral spike,
with the exception of cysteine-linked SOS/IP glycopro-
teins (Binley et al., 2000; Sanders et al., 2002b; Schulke
et al., 2002), are rendered cleavage defective by design in
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and gp41 glycoprotein subunits (Barnett et al., 2001;
Chakrabarti et al., 2002; Earl et al., 2001; Yang et al.,
2001, 2002; Zhang et al., 2001).Fig. 2. Representative histograms of the percent maximum fluorescence
detected by antibody binding to cleavage-competent and cleavage-defective
JR-FL envelope glycoproteins. The primary antibodies 2G12 and 39F shown
here were used at 10-fold increasing concentrations and the secondary anti-
human IgG-PE was used in excess (see Materials and methods).Results
Viral neutralizations
To establish that the envelope glycoproteins and anti-
bodies that we used in the study were consistent in their
properties with previously published studies, we sought to
determine the neutralization activity of a selected panel of
monoclonal antibodies that had an expected range of
capacity to neutralize relatively resistant primary isolates.
Therefore, we performed neutralization assays of selected
antibodies against the primary isolates JR-FL and YU2.
Representative neutralization curves were generated (Fig.
1) and the derived neutralization IC50 and IC90 values are
summarized (Table 1). As expected, the ligands that could
neutralize JR-FL and YU2 at the concentrations tested
were IgGb12 [CD4 binding site (CD4BS)] (Burton et al.,
1994), four domain-soluble CD4 (sCD4) and pooled IgG
from HIV-infected patients (HIVIG). The antibody 2G12
(anti-carbohydrate) (Trkola et al., 1996) neutralizes JR-FL
but not YU2, presumably since YU2 lacks a critical glycan
required for efficient 2G12 binding (Sanders et al., 2002a;
Scanlan et al., 2003). Those monoclonal antibodies tested
that could not neutralize JR-FL and YU2 were the two
CD4BS monoclonal antibodies F105 and IgGb6, the CD4-
induced (CD4i) monoclonal antibody 17b, the V3 loop
monoclonal antibody 39F, and N- and C-termini epitope
monoclonal antibodies, C11 (C1/C5 conformational) and
211c (C1/C4 conformational) (Moore and Sodroski, 1996;
Posner et al., 1993). It is interesting to note that as
previously observed (Koch et al., 2003; Sullivan et al.,
1995), the antibodies that have the ability to neutralize lab-
adapted isolates (IgGb6, F105, 39F, and 17b) all exhibit
some enhancement of primary isolate entry at the higher
antibody concentrations, whereas the antibodies that cannot
neutralize any virus (C11 and 211c) do not display
enhancement of viral entry (not shown).Table 1
JR-FL and YU2 IC50 and IC90 neutralization values by ligands (Ag/ml)
Virus Neutralizing antibodies Non
IgGb12 sCD4 HIVIG 2G12 F10
JR-FL
IC50 0.1 4.6 4.1 0.2 NN5
IC90 2.2 10.4 28.1 1.8
YU2
IC50 5.9 0.4 3.2 NN50
b NN5
IC90 72.4 13.1 12.0
a denotes antibody-mediated enhancement of entry.
b NN50 indicates IC50 and IC90 values were greater than the highest concentratioFACS cell-surface staining of JR-FL envelope glycoproteins
For cell-surface staining analysis, the HIV Env glyco-
proteins were deleted of their cytoplasmic tails, which has
been shown previously to enhance cell surface expression of
these oligomers (Berlioz-Torrent et al., 1999; LaBranche et
al., 1995; Si et al., 2001). The 293T cells transfected with
the plasmids encoding cleavage-competent JR-FL 160
glycoproteins, and the cleavage-defective homologue, were
stained with a panel of monoclonal antibodies and sCD4
and were analyzed by FACS as described previously (Koch
et al., 2003). A representative set of FACS histograms for
the 2G12 and 39F antibodies at selected concentrations is
shown in Fig. 2. The mean fluorescence intensities of each
ligand at each concentration tested were derived from the
FACS histograms and were used to generate the binding
curves shown in Fig. 3.
By inspection of the binding curves, it is readily
apparent that only the neutralizing ligands efficiently
recognized the cleavage-competent JR-FL glycoproteins
(Fig. 3; compare panel A to B, closed boxes). Interestingly,
only the neutralizing ligands 2G12, IgGb12, and sCD4
achieved saturation binding of the JR-FL cleavage-com--neutralizing antibodies
5 IgGb6 39F 17b 211C C11
0a NN50a NN50a NN50a NN50 NN50
0 NN50 NN50 NN50 NN50 NN50
n tested, 50 Ag/ml.
Fig. 3. FACS-based cell-surface staining curves of JR-FL cleavage-
competent (n) and cleavage-defective (5) envelope glycoproteins. (A)
Neutralizing ligands: 2G12, IgGb12, sCD4, HIVIG, and the negative control
human IgG1 antibody anti-RSV. (B) Non-neutralizing antibodies: F105,
IgGb6, 39F, 17b, 211c, and C11. The data shown for all the monoclonal
antibodies are from the same representative experiment performed with
duplicate samples. Error bars indicate the range of values obtained for the
duplicate samples; most are not visible due to the precision of the assay and
the size of symbols. The analysis was repeated in five independent
experiments with similar results. Data for the neutralizing ligands sCD4
and HIVIG were extracted from another representative experiment and the
MFI values were normalized by using 2G12 (see Results).
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cleavage-competent glycoproteins by these ligands is
consistent with their neutralization potency and presumed
affinity for the functional spike (Fig. 3 and Table 1). The
concentration of HIVIG needed to achieve detectable
staining was considerably greater than the monoclonal
antibody concentration (Fig. 3A), consistent with its
relatively lower neutralizing potency (Table 1) and the
deduction that only a minor fraction of IgG in the pool of
immunoglobulins possesses HIV-1 neutralizing capacity.
Consequently, we concluded that the HIVIG was not a
reliable reagent to determine the level of expression
between cleavage-competent or cleavage-defective enve-
lope glycoproteins. Accordingly, we used 2G12 to assess
the level of expression for the JR-FL glycoproteinsexamined here, as was done previously for other HIV-1
envelope glycoproteins (Si et al., 2003). For the FACS
stainings shown with all the monoclonal antibodies in Fig.
3, it was not necessary to normalize the data since the two
forms of the JR-FL Env were present at similar levels on
the cell surface as determined by the quantitative 2G12
binding (Fig. 3).
In stark contrast to the neutralizing ligands, the non-
neutralizing antibodies did not display significant binding to
the cleavage-competent JR-FL glycoproteins (Fig. 3B).
Both the neutralizing and non-neutralizing antibodies
efficiently recognized the JR-FL cleavage-defective enve-
lope glycoproteins (Fig. 3; panels A and B). By inspection
of the binding curves in Fig. 3B, it is apparent that the
recognition of the JR-FL cleavage-defective envelope
glycoprotein by the non-neutralizing antibodies increases
dramatically in both magnitude and apparent affinity
compared to recognition of the cleavage-competent proteins
by these antibodies. These data suggest that the non-cleaved
envelope glycoproteins adopt a conformation that is differ-
ent from that of the cleavage-competent envelope glyco-
proteins allowing the non-neutralizing antibodies to readily
access their epitopes only on the non-cleaved spikes.
At the higher antibody concentrations used in this study,
there was non-saturating, low-level binding to the JR-FL
cleavage-competent proteins detectable by the IgGb6, F105,
39F, and 17b antibodies. These levels were slightly above
the background levels determined by the anti-RSV IgG-
negative control antibody. Such low-level binding is
consistent with the enhancement of viral entry observed at
similar antibody concentrations with these antibodies (Fig.
1). Enhanced viral entry mediated by Env-specific anti-
bodies implies that there must be some interaction by these
antibodies with the viral envelope glycoproteins, and hence
low-level binding might be expected. In contrast, the non-
neutralizing and non-enhancing C11 antibody displayed no
consistent binding above the anti-RSV IgG negative control
levels.
FACS staining of the YU2 envelope glycoproteins
For cell-surface expressed YU2 envelope glycoprotein,
we could not detect any differences in recognition by
neutralizing and non-neutralizing antibodies of the YU2
cleavage-competent or cleavage-defective envelope glyco-
protein spikes (Fig. 4). These data were consistent with our
earlier report in which both cleavage-competent and
cleavage-defective YU2 envelope glycoproteins were equiv-
alently recognized by several non-neutralizing antibodies
(Grundner et al., 2002). In the experiments presented here,
IgGb12 was used to normalize the mean fluorescence values
as a threefold difference in expression was noted between
the YU2 cleavage-defective and cleavage-competent glyco-
proteins. In other experiments, we more closely equilibrated
the expression level by adjusting the DNA amount to be
transfected into cells (sixfold more for the YU2 cleavage-
Fig. 4. Representative FACS-based cell-surface staining curves of YU2
cleavage-competent (.) and cleavage-defective (o) envelope glycoproteins
with IgGb12, HIVIG, F105, and 39F and the negative control human IgG1
antibody, anti-RSV. The data shown are from the same representative
experiment performed with duplicate samples. Error bars indicate the range
of values obtained for the duplicate samples and are shownwhere visible. The
analysis was repeated in three independent experiments with similar results.
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expression, the cleavage-defective and cleavage-competent
glycoproteins were equally recognized by all antibodies (not
shown).Fig. 5. Western blot analysis of envelope glycoproteins from supernatants, total
envelope glycoproteins of JR-FL (left) and YU2 (right) was probed with anti-gp120
from the cell lysate (Total cell) and from cell-surface biotinylation and avidin–
molecular weight form of gp160 was designed as gp160H. (B) Left, the ni
immunoprecipitated with HIVIG was probed with streptavidin–HRP. (B) Right, in
and anti-actin monoclonal antibody. Note that the bTotal cellQ as labeled repres
immunoprecipitate of the lysate.Analysis of envelope glycoprotein expression in transfected
cells
To demonstrate the underlying mechanism for the
restricted recognition of the JR-FL cleavage-competent
envelope glycoproteins by neutralizing ligands, we sought
to determine the level of cleavage of the JR-FL glycopro-
teins possessing the wild-type REKR cleavage motif
compared to the cleavage-defective SEKS glycoproteins.
From our initial analysis, we observed that the JR-FL gp160
glycoproteins are partially cleaved in the total cell lysate as
both a gp160 species and a gp120 protein species could be
detected (Fig. 5A, 2nd lane). Next, we used cell surface
biotinylation and avidin–agarose precipitation to determine
the degree of envelope glycoprotein cleavage on the cell
surface that we had examined by the FACS binding
analysis. The fraction of the JR-FL envelope glycoproteins
that were accessible to biotinylation on the cell surface
appeared to be fully cleaved. We concluded so because only
a gp120 protein species could be detected in biotinylated
samples that had been immunoprecipitated by the avidin–
agarose beads, transferred to nitrocellulose and probed with
polyclonal anti-gp120 rabbit sera (Fig. 5A, 3rd lane). To
confirm these data, we then subjected the same blot tolysate, or cell surface biotinylation. (A) The nitrocellulose blot containing
rabbit sera. Shed gp120 from supernatants, gp160 and gp120 glycoproteins
agarose immunoprecipitated lysate (Cell surface) are indicated. A higher
trocellulose blot containing envelope glycoproteins of JR-FL and YU2
two repeat experiments, the blots were probed with anti-gp120 rabbit sera
ents 20 Al of the cell lysate whereas the bCell surfaceQ represents a 1 ml
Fig. 6. Western blot analysis of JR-FL cleavage-defective envelope
glycoproteins enzymatically deglycosylated by addition of Neuraminidase
and/or EndoH and probed with anti-gp120 rabbit sera. The hyperglycosy-
lated form was designated gp160H and the deglycosylated gp160
glycoprotein was designated gp160D.
Fig. 7. FACS-based cell-surface staining curves of YU2 cleavage-defective
(SEKS), cleavage-competent (REKR), and cleavage-competent/furin
(REKR + furin) envelope glycoproteins with IgGb12 (open symbols) and
39F (closed symbols). In this experiment, the YU2 SEKS proteins were
better expressed than the YU2 REKR proteins.
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body to detect only biotinylated proteins at the cell surface
previously immunoprecipitated with HIVIG. The JR-FL
cleavage-competent lane that had appeared to be completely
cleaved by probing with the gp120 antisera did have a small
level of residual non-cleaved gp160 detectable at the cell
surface when probed with the streptavidin–HRP (Fig. 5B,
1st lane). The detection of residual gp160 by the second
method might be due to the sensitivity of detection or a
biased recognition of the gp120 antisera; however, this same
sera could detect the non-cleaved JR-FL gp160 in the cell
lysate with apparently reasonable sensitivity (Fig. 5).
Since the demonstration that efficient cleavage of the
JR-FL cleavage-competent (REKR) glycoproteins was the
underlying basis to observe the correlation of binding with
neutralization, we repeated the critical cell-surface bio-
tinylation experiment several additional times to confirm
the reproducibility of the data (see Fig. 5B, right panel).
We determined that high cell viability (N95%) and fresh
biotinylation reagents were needed to reproducibly observe
efficient cell-surface cleavage by this method. We included
the additional control of immunoblotting for actin in both
the total cell lysate and in the (presumably) cell-surface-
only biotinylated protein compartment. The presence of
actin in the biotinylated and avidin–agarose-precipitated
samples would indicate that there had been significant
labeling of interior cell proteins and that cell surface
specificity had not been adequately maintained. For the
two experiments shown in the right panel of Fig. 5B, when
the detection of actin in the biotinylated fraction was
proportionately low in comparison to the total cell lysate,
the efficient cleavage of gp160 precursor cleavage to cell
surface gp120 was readily observed. In experiments not
shown, less efficient precursor cleavage was associated
with both lower cell viability and increased levels of
biotinylated actin.As expected, the JR-FL cleavage-defective envelope
glycoproteins analyzed in a similar manner were not
efficiently cleaved (although in this experiment a limited
amount of gp120 could be immunoprecipitated from the
supernatant). Instead, we observed a high molecular Env
glycoprotein form at the cell surface that was the
predominant form of non-cleaved JR-FL glycoproteins
detected on the cell surface by this method (Fig. 5A, 5th
and 6th lanes). This high molecular weight gp160
(gp160H) species has been observed by others (Herrera
et al., 2004) and has been suggested to be due to
hyperglycosylation. Therefore, we performed enzymatic
deglycosylation experiments on gp160H using neuramini-
dase and Endo H. We observed that the higher molecular
weight gp160H envelope glycoprotein form was due in
part to sialic acid modifications but also in part to the
addition of high mannose moieties not normally present on
gp160 (see Fig. 6).
To better understand the lack of difference in antibody
recognition of the YU2 cleavage-competent and cleavage-
defective Env glycoproteins compared to the similar JR-FL
Envs, we performed similar experiments on cleavage-
competent (REKR) and cleavage-defective (SEKS) YU2
envelope glycoproteins. For the YU2 bcleavage-competentQ
envelope glycoproteins, strikingly difference results were
obtained as compared to the JR-FL REKR glycoproteins.
Very little cleavage of gp160 to gp120 was observed in
either the cell lysate (Fig. 5A, 7th lane) or the cell surface
(Fig. 5A, 8th lane) for the YU2 envelope glycoproteins
possessing the wild-type REKR cleavage site.
Similar to the JR-FL cleavage-defective glycoproteins,
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to hyperglycosylation. The overall expression of YU2 Env
was higher than JR-FL Env, so the blot was subjected to
different exposure times to roughly equilibrate the enve-
lope glycoprotein band intensities shown in Fig. 5.
Interestingly, both the JR-FL and YU2 glycoproteins
containing the native REKR cleavage site demonstrated a
different glycosylation pattern from those rendered cleav-
age-defective by mutagenesis (Fig. 6). That is, only the
cleavage-site-modified SEKS proteins displayed the pres-
ence of the more hyperglycosylated form of gp160. This
difference presumably reflects different trafficking of the
REKR-containing as compared to the SEKS-containing
envelope glycoproteins within the cell even though they
differ by only two amino acids in primary sequence and is
not dependent upon efficient enzymatic processing of the
REKR cleavage site.
A logical follow-up experiment was to study the
impact of furin co-expression with cleavage-competent
YU2 Env on precursor cleavage efficiency. As previously
observed in similar experiments (Binley et al., 2002), the
co-expression of furin lowered the expression level of the
envelope glycoproteins but did not have an impact on
cleavage efficiency (Fig. 7). In other experiments not
shown, we examined the endogenous levels of gp160
precursor cleavage of the primary isolate Envs ADA, 89.6
and SF162 by Western blotting of cell lysates following
biotinylation and avidin–agarose precipitation. Even
though these additional envelope glycoproteins contained
the wild-type REKR cleavage motif, we could not
observe a significant level of precursor cleavage by this
method.Fig. 8. Light microscopy photographs of a cell–cell fusion assay. 293T cells were
expressor plasmids and with (C) YU2 cleavage-competent, and (D) cleavage-defec
indicated by the arrows in panels A and C.Cell–cell fusion analysis
Because the Env glycoproteins that were used for the
cell-surface analysis harbored deletions in the cytoplasmic
tail (to increase cell-surface expression), we felt that it
was prudent to demonstrate that the cleavage-competent
glycoproteins were functional and fusogenic. We per-
formed cell–cell fusion assays using CD4- and CCR5-
dual positive 3T3.T4.CCR5 target cells and 293T Env-
expressing cells. As expected from earlier reports, both
JR-FL and YU2 cleavage-competent envelope glycopro-
teins could form syncytia in the presence of the receptor-
bearing cells whereas JR-FL and YU2 cleavage-defective
glycoproteins could not (Bosch and Pawlita, 1990; Guo
et al., 1990; McCune et al., 1988). Many more and larger
syncytia were observed by cells expressing the cleavage-
competent JR-FL envelope glycoproteins as compared to
cells expressing the cleavage-competent YU2 envelope
glycoproteins. This could be related to differences in
precursor cleavage or could be due to other properties of
the two Envs not defined here (e.g., receptor–coreceptor
affinity; Fig. 8 and Table 2).transfected with (A) JR-FL cleavage-competent and (B) cleavage-defective
tive plasmids and incubated with CD4+ and CCR5+3T3 cells. Syncytia were
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In this study, we have demonstrated a clear and dramatic
difference in the recognition of HIV-1 primary isolate
envelope spike glycoproteins by neutralizing antibodies and
the neutralizing ligand sCD4 compared with that of non-
neutralizing antibodies. We observed that only the neutraliz-
ing antibodies and sCD4 were able to efficiently bind the JR-
FL cleavage-competent envelope glycoproteins, whereas
both neutralizing and non-neutralizing antibodies could
achieve saturation binding of the JR-FL cleavage-defective
glycoproteins. As expected, biochemical analysis confirmed
that cell-surface, cleavage-competent JR-FL envelope gly-
coproteins were efficiently cleaved whereas the cleavage-
defective glycoproteins were not cleaved. As anticipated by
our previous studies (Grundner et al., 2002), we did not
observe the selective recognition of YU2 cleavage-competent
envelope glycoproteins when compared to cleavage-defec-
tive YU2 glycoproteins by neutralizing antibodies or sCD4.
We sought to determine the biochemical differences between
the selective recognition of JR-FL proteins containing the
canonical REKR precursor cleavage site and the lack of
selective recognition of the YU2 REKR envelope glycopro-
teins. Biochemical analysis demonstrated that the YU2
cleavage-competent envelope precursor gp160 glycoproteins
were very poorly cleaved as opposed to the efficiently
cleaved JR-FL REKR glycoproteins. These data indicated
that efficient precursor cleavage is required for selective
recognition of functional spikes by neutralizing ligands and
that the lack of precursor cleavage is likely to be the major
factor influencing the lack of the selective recognition of YU2
cleavage-competent Env by the same neutralizing ligands.
Taken together, we interpret these data to mean that the
HIV-1 envelope glycoprotein precursor cleavage event has a
significant global impact on gp120 envelope glycoprotein
structure. Exposure of non-neutralizing determinants is
associated with inefficient precursor cleavage. On efficiently
cleaved spikes, the non-neutralizing regions become
occluded and only neutralizing determinants remain acces-
sible. Some of the observed differences in precursor
cleavage associated with exposure/occlusion may be due
to the relative level of expression of the selected Env
glycoproteins; that is, that the YU2 glycoproteins were
better expressed than the JR-FL glycoproteins from the rev-
dependent, non-codon-optimized vectors used in this study.
However, we did survey three other primary isolate
envelope glycoproteins expressed from non-codon opti-
mized DNA (ADA, 89.6 and SF162) and we did not
observe efficient cleavage of cleavage-competent glycopro-
teins in cell lysates following biotinylation. It may be that
efficient precursor cleavage, and the associated property of
selective binding of neutralizing ligands, might be limited to
envelope glycoproteins derived from particular strains.
Why such distinct associations, as reported here, have not
been readily observable previously may be due to differences
in precursor cleavage of different primary Envs, the relativelylow level of Env expression from these vectors, or a lack of
coupling the biochemical analysis of Env precursor cleavage
with binding and neutralization. For the biochemical
analysis, we found that to observe efficient cleavage of JR-
FL precursor glycoproteins possessing the wild-type cleav-
age site, it was necessary that the cells displayed high
viability and that the biotinylation of proteins was restricted
to the cell surface. These difficult-to-control variables might
make such associations more difficult to observe. A previous
report did examine FACS-based antibody binding, neutral-
ization capacity, and cleavage site modifications in the
context of glycoproteins derived from the lab-adapted strain
HXBc2 and a SHIV-passaged, neutralization-resistant deriv-
ative virus, HXBC 3.2P (Si et al., 2003). Perhaps, due to
envelope glycoproteins strain differences or incomplete
precursor cleavage of cell-surface glycoproteins, the previous
study arrived at different conclusions in regards to effects of
precursor cleavage on overall Env topology.
The data here are consistent with (although do not
directly support) the model that antibodies or ligands that
are able to bind the Env spike with an affinity great enough
to achieve high-level saturation binding of functional spikes
can then neutralize by steric interference with the fusion
process (Parren et al., 1998). These data are also consistent
with the model that uncleaved Env either on cell surfaces or
in cellular debris may present epitopes that elicit many non-
neutralizing antibodies as has been suggested previously
(Parren et al., 1997).
The conclusions of our study have an obvious and
important implication for envelope glycoprotein subunit
vaccine design. Many approaches to make soluble mimics
of the native functional spike eliminate the precursor
cleavage site to promote gp120–gp41 stability (Barnett et
al., 2001; Earl et al., 2001; Srivastava et al., 2003a; Yang et
al., 2000, 2001, 2002). However, as shown in this study, it
appears that modifying the cleavage site allows better access
of the non-neutralizing antibodies to elements of the spike
occluded on cleaved Env. Thereby, the use of cleavage-
defective Env, without further alterations, may not be
optimal for envelope glycoprotein immunogen design if
the goal is to preferentially expose only neutralizing
determinants. A previous study has suggested that inocu-
lation with DNA encoding cleavage-competent DV2gp140
molecules followed by inoculation with cleavage-defective
DV2gp140 glycoproteins more efficiently elicited neutraliz-
ing antibodies than when cleavage-defective DNA and
proteins were used throughout the immunization protocol
(Srivastava et al., 2003b). Alternatively, it is possible that by
altering cleavage-defective immunogens by stabilizing
mutations or occlusion by the addition of glycans might
overcome the antigenic exposure of non-neutralizing deter-
minants, although the structural impact might be less clear
(Pantophlet et al., 2003; Xiang et al., 2002). Other strategies
to maintain the native cleavage site, such as the cysteine
linkage of g120 and gp41 in the so-called SOS proteins,
may have some advantages (Binley et al., 2000; Sanders et
M. Pancera, R. Wyatt / Virology 332 (2005) 145–156 153al., 2002b; Schulke et al., 2002). However, it is not clear if
these proteins were subject to the same analysis as described
here that they would be preferentially recognized by
neutralizing ligands. In a similar cautious vein, these data
also suggest that it is not a given that expression of a
primary Env from better-expressed codon-optimized DNA
or from any of the currently available viral vectors will
present efficiently cleaved and preferentially exposed
neutralizing epitopes to the immune system. An obvious
limitation to in vivo expression, which might be difficult to
control, would be to exceed the natural precursor cleavage
capacity of an expressing cell type. It is possible that co-
expression of furin coupled with additional modifications of
the native cleavage site may have to be included in a
strategy that will increase the likelihood that efficiently
cleaved envelope glycoproteins will be presented to the
immune system as has been previously suggested for the
SOS approach (Binley et al., 2000, 2002). Obviously, we
would like to translate the observations made here to
vaccine design, but this may not be entirely straightforward
due to the reasons just stated. However, several strategies
can still be pursued including the elucidation of primary
Envs that selectively expose neutralizing determinants,
presumably due to more efficient Env precursor cleavage.Materials and methods
Virus neutralization assays
Viral neutralization assay were performed as previously
described (Mascola et al., 2002). Briefly, on day 1, 40 Al of
virus stock solution of JR-FL-GFP (green fluorescence
protein) and YU2-GFP was incubated with 10 Al of a panel
of monoclonal antibodies (2G12, IgGb12, F105, IgGb6,
sCD4, 39F, 17b, C11, and 211C) at concentrations up to 50
Ag/ml and up to 10,000 Ag/ml of HIVIG at 37 8C for 30
min. Next, 20 Al (105 cells) of peripheral blood mono-
nuclear cells (PBMC) (IL-2 medium; JR-FL) or A3R5 (G-
418; YU2) (Kim et al., 2003) were added to the wells.
Different target cells were necessitated for YU2 because
YU2 infects PBMCs very inefficiently (Kim et al., 2003).
On day 2, the cells were fed with 150 Al of the
corresponding medium RPMI 1640, 1% l-glutamine, 1%
penicillin–streptomycin (pen-strep), 10% fetal bovine serum
(FBS), and 500 U IL-2 for PBMC and 50 Ag/ml G-418 for
A3R5. Forty-eight hours after infection (day 3), the cells
were transferred into 96-well V bottom plate (Corning) and
resuspended in 200 Al FACS staining buffer [phosphate
buffered saline (PBS), 5% heat-inactivated FBS, 0.02%
azide] containing 2% paraformaldehyde. The quantitation of
HIV-1-infected cells was done by flow cytometry on a
Beckman Coulter Calibur. Percentage residual entry is the
level of entry observed in the presence of a given ligand at a
specific concentration and is determined as follows: %
residual entry = 100%  % neutralized. One hundredpercent entry is defined by entry with no neutralizing ligand
present. IC50 and IC90 were calculated from these data.
Transfection of envelope glycoprotein plasmids
One day prior to transfection, 8  106 293T cells in
DMEM, 10% FBS, 1% pen-strep were seeded in a 150-mm
tissue culture dish. The cells were transfected with the
pSVIII expressor plasmids encoding JR-FL and YU2 160
glycoproteins, wild-type (cleavage-competent) and cleav-
age-defective, along with co-transfection of the pctat
expressor, using Fugene6 (Roche) at a ratio DNA/Fugene6
1:3 and 5 Ag per 1  106 cells. The only difference between
cleavage-competent and cleavage-defective envelope gly-
coproteins, which was confirmed by sequencing, was a
subtle and conservative change, introduced by Quick
Change mutagenesis at the natural gp120-gp41 cleavage
site boundary of REKR to SEKS (residues 508–511,
HXBc2 numbering (Korber et al., 1998). For co-transfection
of furin, the expressor plasmid encoding cleavage-compe-
tent YU2 160 glycoproteins and the expressor plasmid
encoding furin were co-transfected in 293T cells at a 1:1
DNA ratio using Fugene6.
Fluorescence-activated cell sorting (FACS) staining
FACS staining was performed as previously described
(Koch et al., 2003). Forty-eight hours following trans-
fection, the cells were harvested and washed in FACS buffer
(PBS, 5% FBS, 0.02% azide) and stained with a panel of
monoclonal antibodies used for the viral neutralization
assay. The monoclonal antibodies were washed in FACS
buffer and anti-human phycoerythrin (PE) (Sigma) at a 1:70
dilution was added for 30 min and then washed to remove
unbound secondary antibody. To detect sCD4 staining to
cell-surface Env, sCD4 (Progenics) was incubated for 1 h
with the transfected cells, washed, and then the anti-human
CD4 monoclonal antibody Q425 (Healey et al., 1990) was
added to the cells for 45 min in FACS buffer with 1 AM
CaCl2. Following another wash, anti-mouse IgG R-PE
(Jackson Laboratory) was added at 1:100 dilution to the
cells for 30 min, then washed in FACS buffer. The stained
cells were analyzed by FACS on a Beckman Coulter Calibur
Instrument.
Cell-surface biotinylation, Western blotting, and
deglycosylation of proteins
Forty-eight hours following transfection, the cells were
harvested and washed in PBS, pH 8. Biotinylation of all
proteins on the cell surface was performed using a
nonpermeable biotin reagent, EZ-link Sulpho-NHS-LC-
Biotin (Pierce) for 30 min at 4 8C. The cells were then
washed in PBS and lysed in TSA buffer (10 mM Tris, 0.15
M NaCl, pH 8) containing 1% NP40 for 30 min on ice. The
lysates were centrifuged at maximum speed in an eppendorf
M. Pancera, R. Wyatt / Virology 332 (2005) 145–156154centrifuge for 20 min. One milliliter of the clarified 293T
cell lysates was immunoprecipitated with immobilized
avidin–agarose beads (Amersham) and in a similar manner
with HIVIG and proteinA-agarose (Sigma). Alternatively,
the cells were labeled directly on the plate per manufactur-
er’s instructions, using the Cell Surface Protein Biotinyla-
tion and Purification Kit from Pierce. For Western blotting,
20 Al of total cell lysate or the immunoprecipitates were
subjected to SDS-gel electrophoresis, transferred to nitro-
cellulose membranes, and blotted with either rabbit anti-
gp120 (1:500) followed by an anti-rabbit IgG-HRP (horse-
radish peroxidase, 1:10,000, Sigma) or streptavidin-HRP
(1:20,000, Pierce).
To determine that the biotinylation was specific for cell
surface proteins, duplicate blots from the same lysates and
immunoprecipitates were probed with anti-actin (1:5000,
Jackson Laboratory) followed by an anti-mouse IgG-HRP at
1:5000 (Sigma).
For the deglycosylation of cleavage-defective Env
glycoproteins, lysates were treated overnight at 37 8C with
neuraminidase and/or Endo H (5 Al of enzyme in 20 Al
lysate) in 50 mM Sodium Citrate (pH 6.0 at 25 8C) and
analyzed by Western blotting.
Cellular fusion assays
Forty-eight hours after transfection, 105 envelope glyco-
protein-expressing effector cells were mixed with 105
receptor-bearing cells (3T3.T4.CCR5 cells stably expressing
CD4 and CCR5) in DMEM, 10% FBS, 1% pen-strep and
dispensed into wells of a 96-well tissue culture plate. The
effector and receptor-bearing target cells were incubated for
24 h at 37 8C. Syncytia were counted on a Nikon Eclipse
light microscope and photographs were taken with a Nikon
Coolpix digital camera.Acknowledgments
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